Leukaemia drug wows conference goers

Among the crowd of haematologists at the Sydney Hilton for the international workshop on chronic lymphocytic leukaemia, I encountered Dr Constantine Tam, who presented a paper on venetoclax, a drug nipping the heels of the two B cell receptor antagonists currently revolutionising CLL treatment.

Venetoclax is still in Phase 3 clinical trials, says Dr Tam of the Peter MacCallum Cancer Centre, who is enthusiastic about its prospects. It is a BCL2 (B cell Lymphoma 2) inhibitor which